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Background: Hypertension is a major risk factor for renal disease progression. However, the mechanisms by which
hypertension aggravates the effects of diabetes on the kidney are incompletely understood. We tested the
hypothesis that renovascular hypertension accelerates angiotensin-II-dependent kidney damage and inflammation
in the db/db mouse, a model of type II diabetes.
Methods: Renovascular hypertension was established in db/db and wild-type control mice through unilateral renal
artery stenosis (RAS); the non-stenotic contralateral kidneys evaluated 2, 4 and 6 weeks later. Angiotensin-II infusion
(1000 ng/kg/min), unilateral nephrectomy, or both were also performed in db/db mice to discern the contributions
of hypertension versus hyperfiltration to development of chronic renal injury in db/db mice with RAS. The effect
of blood pressure reduction in db/db mice with RAS was assessed using angiotensin-receptor-blocker (ARB) or
hydralazine treatment.
Results: Db/db mice with renovascular hypertension developed greater and more prolonged elevation of renin
activity than all other groups studied. Stenotic kidneys of db/db mice developed progressive interstitial fibrosis,
tubular atrophy, and interstitial inflammation. Contralateral kidneys of wild type mice with RAS showed minimal
histopathologic abnormalities, whereas db/db mice with RAS developed severe diffuse mesangial sclerosis,
interstitial fibrosis, tubular atrophy, and interstitial inflammation. Db/db mice with Angiotensin II-induced hypertension
developed interstitial lesions and albuminuria but not mesangial matrix expansion, while nephrectomized db/db mice
exhibited modest mesangial expansion and interstitial fibrosis, but not significant albuminuria. The combination of
unilateral nephrectomy and angiotensin II infusion reproduced all the features of the injury albeit in a less severe
manner. ARB and hydralazine were equally effective in attenuating the development of mesangial expansion in
the contralateral kidneys of db/db mice with RAS. However, only ARB prevented elevation of urinary albumin/
creatinine in db/db mice with RAS.
Conclusion: Renovascular hypertension superimposed on diabetes exacerbates development of chronic renal
disease in db/db mice at least in part through interaction with the renin-angiotensin system. Both ARB and hydralazine
were equally effective in reducing systolic blood pressure and in preventing renal injury in the contralateral kidney of
db/db mice with renal artery stenosis. ARB but not hydralazine prevented elevation of urinary albumin/creatinine in
the db/db RAS model.
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Diabetic nephropathy is the leading cause of end-stage renal
disease in the United States. In 2008, 44% of new cases of kid-
ney failure were attributed to diabetes, and the numbers are
expected to increase as the number of Americans with diag-
nosed diabetes has reached above 20 million – with another
estimated 7 million people with undiagnosed diabetes [1].
Hypertension is a major risk factor for renal disease
progression in patients with diabetes. One of the most
common causes of secondary hypertension is renal ar-
tery stenosis (RAS). Atherosclerosis, the main cause of
RAS, shares many similar risk factors with diabetes type
II, thereby making it likely for RAS to co-exist in dia-
betic type II patients. Indeed, in patients with type II dia-
betes and hypertension the incidence of RAS is between
17-44% [2-4] and even subcritical RAS confers a signifi-
cant risk for progression to renal failure [3]. However, it
is still unclear if this increased risk is due to hyperten-
sion alone or contributed by other factors that are in-
duced during RAS. It is well recognized that RAS is
associated with activation of the renin-angiotensin sys-
tem which leads to systemic hypertension. We have pre-
viously demonstrated that in our unilateral RAS model,
the decrease in blood flow to the stenotic kidney is asso-
ciated with an increase in blood flow to the contralateral
kidney [5], raising the possibility that the contralateral
kidney may be susceptible to hyperfiltration injury. However,
few studies have directly addressed potential interactions be-
tween hyperfiltration and pathophysiologic activation
of renin-angiotensin system in the development of dia-
betic renal disease.
We therefore sought to test the hypothesis that activa-
tion of the renin-angiotensin system and hyperfiltration
interact to produce chronic injury in the contralateral,
non-stenotic kidney of db/db mice. We demonstrate that
db/db mice with RAS develop diffuse mesangial sclerosis
in their contralateral kidney that is not observed in age
matched db/db mice or in WT mice with RAS. Unilat-
eral nephrectomy, infusion of Angiotensin II, or their
combination in age-matched db/db mice failed to repro-
duce the glomerular and, in particular, the interstitial lesions
observed in db/db mice subjected to RAS. Prophylactic ad-
ministration of hydralazine and valsartan yield only modest
attenuation of renal damage in the contralateral kidney of
db/db mice with RAS, with no difference between the two
interventions. We conclude that renovascular hypertension
in diabetic db/db mice produced accelerated and progressive




C57BLKS (WT) (N = 50) and C57BLKS/JLepr (db/db)
(N = 166) male mice, 5–6 weeks old, were obtained fromJackson Laboratory (Bar Harbor, ME). Induction of
hypertension and RAS was performed using a modified
cuff approach as previously described [5,6] at 6–7 weeks
of age (N = 10 for each time points). Mice were studied
at 2, 4 and 6 weeks post RAS induction. Sham surger-
ies (N = 5 for each time points) consisted of a flank in-
cision and mobilization of the renal artery without
placement of a cuff. To determine the effect of angio-
tensin II induced hypertension with or without hyper-
filtration, unilateral nephrectomies or sham surgeries
[7,8] were performed on db/db mice at 6–7 weeks of
age as previously described. Osmotic mini-pump (Alzet
model 2004, Durect, Cupertino, CA) loaded with Angio-
tensin II (1000 ng/kg/min) or PBS were inserted subcuta-
neously on the same day [9-13]. To determine the effect
of lowering blood pressure, Hydralazine (10 mg/kg/day)
or angiotensin II receptor blocker Valsartan (8 mg/kg/day)
was administered in drinking water of db/db mice with
RAS on the day of the surgery (N = 10 per each treatment,
N = 8 for vehicle treatment).
Blood pressures were measured on conscious acclima-
tized mice using tail cuff method (CODA System, Kent
Scientific, Torrington, CT) three days prior to surgery
and subsequently at two-week intervals. Mice were eu-
thanized by exsanguination at 2, 4, and 6 weeks post-
surgery. Kidneys and hearts were perfused with sterile
PBS, excised, weighed, and either preserved immediately
for histology, or shock frozen in liquid nitrogen for
Western blotting and PCR analysis. All animal protocols
were approved by the Mayo Clinic Institutional Animal
Care and Use Committee.
Biochemical analysis
Blood was collected by tail bleed for serial measure-
ments and finally by terminal bleed. The plasma fraction
was separated by centrifugation upon collection and
stored at −80°C until assay. Renin activity in plasma was
assessed via production of angiotensin I from angiotensi-
nogen using a commercially available GammaCoat Plasma
Renin Activity 125I RIA kit (DiaSorin, Stillwater, MN),
using porcine angiotensinogen (A2283, Sigma-Aldrich, St.
Louis, MO) substrate. Urine albumin and creatinine were
measured on spot urine sample using Albuwell and Cre-
atinine kit (Exocell, Philadelphia, PA). Commercially avail-
able ELISA kits were used for the measurements of serum
CCL2 and IL-6 (R&D Systems, Minneapolis, MN).
Histology and immunohistochemistry
Kidneys were fixed with 10% neutral buffered formalin
and processed for histology or immunostaining using
standard techniques. Histological section (5 μm thick)
were prepared and stained with hematoxylin-eosin (H&E),
Masson’s trichrome, periodic acid-Schiff, anti-fibronectin
(Abcam, Cambridge, MA), and anti-F4/80 (AbD Serotec,
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glomeruli area and diameter. Atrophy was semi quantita-
tively assessed by a renal pathologist by assessing the rela-
tive surface area occupied by atrophic tubules compared
to the total cortical surface area, as previously described
[14]. Mesangial matrix expansion was assessed in PAS sec-
tions with a 0–4 scale (0 = normal, 1 =mild mesangial
matrix expansion, 2 =moderate matrix expansion with pa-
tent capillaries, 3 = severe matrix expansion with seg-
mental capillary loop consolidation, 4 = severe matrix
expansion with global capillary loop consolidation).
Each glomerulus was scored positive or negative for fi-
bronectin, and quantified as percent positive glomeruli
over total glomeruli per tissue sections. Degree of fi-
brosis was quantified in trichrome sections by assess-
ment of ratio of surface area of the cortical area (avoiding
great vessels and glomeruli) at 200× magnification. Inter-
stitial fibronectin deposition and renal microphage infil-
tration was similarly quantified in fibronectin and F4/80
sections respectively. All measurements and quantification
were performed in a random blinded fashion using an
Olympus BX50 microscope (Olympus America, Melville,
NY), a Micropublisher 3.3 RTV camera (Q-Imaging,
Surrey, BC), and the NIS Elements Imaging Software
(Nikon Instruments, Inc., Melville, NY).
Transmission electron microscopy
For transmission electron microscopy, tissue was re-
moved from the paraffin block and placed into warm xy-
lene for 90 minutes, transferred to warm absolute ethanol
for 30 minutes, then transferred to decreasing concentra-
tions of ethanol to 60% then placed into Trump’s fixative
(1% glutaraldehyde and 4% formaldehyde in 0.1 M phos-
phate buffer, pH 7.2) for overnight fixation. Tissue was
then rinsed in 0.1 M phosphate buffer, pH 7.2, post-fixed
in 1% osmium tetroxide for one hour, rinsed in distilled
water, dehydrated, embedded in Spurs resin, and sectioned
at 90 nm. Micrographs were taken on a Philips Technai
12 (FEI, Hilsboro, OR) operating at 80KV. Glomerular
basement membrane measurement was performed by
Mayo Clinic Electron Microscopy Core Facility in a ran-
dom blinded fashion.
mRNA analysis
Total RNA was extracted with RNeasy Mini Plus kit
(Qiagen, Valencia, CA) and reversed transcribed using
iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).
Gene expression analysis was determined by quantitative
real-time PCR using CFX96 (Bio-Rad, Hercules, CA)
and normalized to 18 s. The following primers were
used: Ren1 forward 5’ –GAG GTA GCG ACC CGC
AGC ATT AT- 3’; Ren1 reverse 5’ – GCG CTG CCT
CCC AGG TCA AA- 3’; Ccl2 forward 5’ – AGC ACC
AGC ACC AGC CAA CTC – 3’; Ccl2 reverse 5’ – TGGATG CTC CAG CCG GCA ACT – 3’; Il-6 forward 5’ –
TGG TGA CAA CCA CGG CCT TCC – 3’; 1 l-6 re-
verse 5’ – TAA GCC TCC GAC TTG TGA AGT
GGT – 3’; 18 s forward 5’ – CTC AAC ACG GGA
AAC CTC AC – 3’; 18 s reverse 5’ – CGC TCC ACC
AAC TAA GAA CG – 3’.
Statistical analysis
Data are presented as mean ± SE. Comparisons between
two groups were done using student t-test for paramet-
ric data and Mann–Whitney test for non-parametric
data or data without normal distribution. To assess in-
teractions between time points and multiple groups,
two-way ANOVA followed by a Tukey adjustment for
post-hoc comparison across different time points and
treatment groups was used. For comparison across mul-
tiple groups, one-way ANOVA followed by a Tukey ad-
justment was used for post-hoc comparison of the
measurements. P values <0.05 were considered significant.
Statistical analyses were performed with Graphpad Prism
6 (GraphPad Software, La Jolla, CA).
Results
Wild type (WT) and db/db mice with RAS develop similar
degree of hypertension
To determine the effect of renovascular hypertension on
the development of diabetic nephropathy in the diabetic
db/db mouse, we subjected db/db and wild type mice to
unilateral RAS surgery (db RAS and WT RAS) or to
sham surgery (db sham and WT sham). WT and db/db
mice had similar baseline systolic blood pressure prior
to RAS surgery. Both db RAS and WT RAS experienced
a similar increase in systolic blood pressure 2 weeks
post-surgery that peaks at 4 weeks and remains elevated
at 6 weeks (Figure 1A). WT RAS and db RAS mice
had similar increases in plasma renin activity at 2 weeks
(Figure 1B). However, while plasma renin in WT RAS
mice returned to baseline levels after 4 weeks, plasma
renin in db RAS mice was further increased at 4 weeks be-
fore going back to baseline levels at 6 weeks (Figure 1B).
To determine whether this increase in renin activity
was due to increased renin production or increased en-
zyme activity, we performed RT-PCR analysis of Ren1
expression in the stenotic (Figure 1C) and contralateral
kidneys (Figure 1D). As expected, induction of Ren1 was
much greater in the stenotic kidney (Figure 1C) than
the contralateral kidney (Figure 1D). At 2 weeks, Ren1
expression was increased by 15-fold in the stenotic
kidney of WT RAS (p = 0.026 vs. baseline) and in-
creased by 10-fold in the db RAS (p = 0.289 vs. base-
line). At 4 weeks, Ren1 mRNA levels did not further
increase in WT RAS mice, but was further induced by
150-fold in db RAS mice (p < 0.001 vs. baseline, p <













































































































































































Figure 1 Db RAS and WT RAS mice developed similar degree of hypertension. A. Systolic blood pressure (BP) of db and WT mice subjected
to RAS or sham surgery. Both WT RAS and db RAS experienced similar elevation of systolic BP (WT RAS vs. db RAS, p = ns) compared to their
sham control. B. Plasma renin activity in the db and WT mice subjected to RAS or sham surgery as measured by Angiotensin I production.
C-D. RT-PCR analysis of Ren1 mRNA as normalized to 18 s in stenotic (C) and contralateral kidneys (D) of db and WT mice subjected to
RAS or sham surgery, relative to baseline. E. Ratio of heart weight to tibial length of db and WT mice subjected to RAS or sham surgery.
Data are presented as means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. WT sham. §§ p < 0.01, §§§ p < 0.001 vs. WT RAS. †† p < 0.01,
††† p < 0.001 vs. db sham. Statistical significance was determined by 2-way ANOVA followed by Tukey adjusted post-hoc comparison.
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both WT RAS and db RAS (Figure 1C). As expected,
Ren1 expression in the contralateral kidney of WT
RAS and db RAS was similarly down regulated at
4 weeks (Figure 1D). Although Ren1 expression in the
WT RAS mice returned to baseline level by 6 weeks,
Ren1 expression in the contralateral db RAS kidneyremained down regulated (p < 0.001 vs. baseline, p <
0.001 vs. WT sham, WT RAS, or db sham).
The hearts of both WT RAS and db RAS underwent
hypertrophy, as evidenced by a 15% increase in heart
weight to tibial length ratio at 2 weeks following surgery
(Figure 1E). However, the hearts were larger in db RAS
mice compared to the WT RAS mice at 4 and 6 weeks.
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mice was associated with renovascular hypertension, in-
creased plasma renin content, increased renal Ren1 ex-
pression, and cardiac hypertrophy. After 4 weeks, the
increase in plasma renin activity, renal Ren1 expression,
and cardiac hypertrophy were greater in db/db mice
than in WT mice subjected to RAS.
The contralateral kidney of db-RAS mice develops accelerated
and progressive renal injury
Although the stenotic kidney of db/db mice developed
severe atrophy, the glomeruli appeared to be protected
from development of diffuse mesangial sclerosis – an
early manifestation of diabetic nephropathy – in accord-
ance with previous reports on the stenotic kidney of dia-
betic patients (data not shown) [15]. Instead, the stenotic
kidney of db/db mice developed tubular atrophy to an ex-
tent similar to that observed in the stenotic kidney of WT
mice at all time-points (Table 1).
As we previously described, the contralateral kidney in
WT mice showed mild glomerular enlargement, with no
significant interstitial fibrosis, tubular atrophy, or intersti-
tial inflammation [5,16]. In striking contrast, the contralat-
eral kidney of db RAS mice developed glomerular
mesangial matrix expansion that was significantly greater
than the contralateral kidney of WT RAS or db sham, as
assessed in PAS-stained sections (Figure 2A, 2B) and de
novo glomerular fibronectin deposition (Figure 2A, 2C).
These histopathologic alterations were observed by
2 weeks following RAS surgery (Figure 2B, 2C) mostly
at the juxtamedullary glomeruli. At all time-points be-
yond baseline, the severity of diffuse mesangial scler-
osis in the contralateral kidney of db RAS mice was
significantly greater than that observed in the contra-
lateral kidneys of db sham mice or in WT RAS mice
(Figure 2B).
In addition to the glomerular lesions, the contralateral
kidney of db RAS mice developed progressive interstitial
fibrosis (Figure 2A, 2D, 2E) significantly greater than
that of db sham mice, WT RAS, or WT sham mice at
the same time point (Figure 2D). Similar patterns were
observed in sections stained for the extracellular matrix
proteins fibronectin (Figure 2E). The extent of inflam-
mation in the contralateral kidney as measured by F4/80+Table 1 Percent atrophy of the stenotic kidney of wild





valueWT RAS db RAS
2 weeks 88 ± 6 74 ± 9 0.278
4 weeks 91 ± 2 88 ± 4 0.378
6 weeks 85 ± 7 96 ± 1 0.173area was also greater in the db RAS mice compared to
both WT RAS and db sham mice (Figure 3A, 3B). We
then performed RT-PCR to measure the level of chemo-
kine (C-C motif) ligand 2 (Ccl2) and interleukin 6 (Il-6)
mRNA in the contralateral kidney (Figure 3C, 3D). Both
were elevated in the contralateral kidney of the db RAS
mice in comparison to both WT RAS and db sham mice,
indicating presence of inflammation that was not apparent
in either the WT RAS or the db sham.
WT RAS mice, but not WT sham mice, developed
transient albuminuria that persisted up to 4 weeks post-
surgery before returning to baseline (Figure 4A). Db
RAS mice, however, developed marked albuminuria (at
least 6-fold higher than db sham mice) that persisted
throughout the observation period (Figure 4A). To de-
termine if basement membrane thickening or podocyte
loss (which is some of the characteristic features of diabetic
nephropathy) contribute to this transient albuminuria, we
performed electron microscopy on the contralateral kid-
neys of db/db and WT mice at 6 weeks of hypertension.
Mean glomerular basement membrane thickness in the
contralateral db RAS kidney was increased by 30% after
6 weeks compared to db sham mice (Figure 4B, 4C, 4E),
and their glomeruli also showed extensive podocyte foot
process effacement (Figure 4D), which was not observed in
the contralateral kidney of db sham, WT sham, or WT
RAS mice.
Angiotensin-II induced hypertension does not reproduce
the renal injury induced by renovascular hypertension in
db mice
A critical role for angiotensin II in the development of
chronic renal disease due to etiologies such as diabetes
and hypertension has long been recognized [9-13]. We
therefore infused db/db mice with angiotensin II (db
Ang-II) or PBS for 4 weeks to test the hypothesis that
the severe chronic renal damage observed in the contra-
lateral kidney of db RAS mice is primarily due to ele-
vated angiotensin II levels. Db Ang-II mice developed
hypertension comparable to that observed in db RAS
mice (Figure 5A) despite lower plasma renin content
(Figure 5B). Unlike the db RAS mice, the db Ang-II
mice showed a minimal increase in mesangial matrix
with no evidence of glomerular fibronectin deposition
(Figure 5C). The mean glomerular PAS mesangial matrix
score in db Ang-II mice was similar to that of db sham
mice, whereas that of db RAS mice was over 4-fold higher
(Figure 5D). Both db RAS and db Ang-II developed simi-
lar degree of tubular atrophy, focal interstitial inflamma-
tion and interstitial fibrosis (Figure 5C, 5E), though the db
Ang-II mice showed slightly less interstitial fibronectin de-
position (Figure 5F).
Despite the lack of mesangial matrix expansion, db

















































































































































Figure 2 Contralateral kidney of db RAS but not WT RAS or db sham mice developed chronic renal injury. A. Representative
histological images of contralateral kidney at 4 weeks post-surgery as stained with periodic acid schiff (PAS), fibronectin (FN), and Masson’s Trichrome.
PAS images are taken at 400× magnification. Fibronectin and trichrome images are taken at 200× magnification. B. Glomeruli of db RAS develop greater
mesangial matrix expansion compared to both WT RAS and db sham mice at all time-points. Mesangial matrix expansion was assessed using the PAS
sections with a 0 to 4 scale (see Methods). C. db RAS but not WT RAS mice develop de-novo fibronectin deposition within the glomeruli. Graph showed
% fibronectin positive glomeruli to total number of glomeruli per histological sections in the db RAS mice. No fibronectin positive glomeruli
were observed in the WT sham, WT RAS, or db sham. D. Interstitial fibronectin deposition is increased in db RAS compared to WT RAS or db
sham mice at all time-points. Interstitial fibronectin deposition was assessed as percent area positive for fibronectin in each 200× field over
the whole cortical areas. E. Interstitial fibrosis is increased to a greater extent in db RAS mice compared to WT RAS mice. Interstitial fibrosis
was assessed using trichrome stained sections at 200× magnification. Data are presented as means ± SE. * p < 0.05, ** p < 0.01, *** p < 0.001
vs. WT sham. § p < 0.05, §§ p < 0.01, §§§ p < 0.001 vs. WT RAS. ††† p < 0.001 vs. db sham. Statistical significance for B, D, and E was determined by
2-way ANOVA followed by Tukey adjusted post-hoc comparison. Statistical significance for C was determined by one way ANOVA followed by
Tukey adjusted post-hoc comparison.





















































































Figure 3 The contralateral kidneys of db RAS but not WT RAS mice develop progressive inflammation. A. Representative immunostaining
of renal macrophages in paraffin section of contralateral kidneys. Macrophages were stained with anti F4/80 antibody. All images are taken at
200× magnification. B. Quantitative analysis of F4/80+ macrophages showed that despite lower baseline F4/80, there was increased infiltration in
the contralateral kidney of db RAS mice but not WT RAS mice. C-D. RT-PCR analysis of CCL2 (C) and IL-6 (D) mRNA normalized to 18 s showed
that contralateral kidney of db RAS mice produces more inflammatory cytokines and chemokines compared to WT RAS and db sham. Data are
presented as means ± SE. † p < 0.05, †† p < 0.01 vs. db sham. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. WT sham. §§§ p < 0.001 vs. WT RAS. Statistical
significance was determined by 2-way ANOVA followed by Tukey adjusted post-hoc comparison to determine corrected p-values.
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Thus, increased interstitial fibrosis and albuminuria, but
not mesangial matrix expansion, can be attributed to
angiotensin-II induced hypertension in db/db mice.
Development of renal injury is accelerated in db RAS than
in db/db nephrectomized mice (db-UNX)
Given that angiotensin II infusion in db/db mice failed
to produce the lesions observed in db RAS mice, we
sought to determine whether increased blood flow to the
remaining kidney in mice with unilateral nephrectomy
(db UNX) was responsible for the development of
mesangial sclerosis, interstitial fibrosis, and tubular atro-
phy. Unlike db RAS mice, db UNX mice did not develop
significant hypertension (Figure 5A), and plasma renin
content was lower than that observed in db RAS or db
sham (Figure 5B). After 4 weeks, db UNX developed
mesangial matrix expansion that was significantly greater
than that observed in db sham or db Ang-II mice, but
less than in the contralateral db RAS kidney (Figure 5C,
5D). As with db Ang-II, db UNX developed more mod-
est interstitial fibrosis compared to db RAS (Figure 5C,
5E) and showed no increased interstitial fibronectin de-
position in comparison to db sham (Figure 5C, 5F). DbUNX developed modest albuminuria, but significantly
less than that observed in db RAS mice (Figure 5G).
The severity of injury in the contralateral db RAS kidney
exceeds that induced by a combination of UNx and
Angiotensin-II induced hypertension
As angiotensin-II induced hypertension and unilateral
nephrectomy replicate only some aspects of injury seen
in the contralateral kidney of the db RAS mice, we then
sought to determine if the combination would produce
the severe injury observed in db RAS mice. We thus in-
fused angiotensin-II into db/db mice subjected to unilat-
eral nephrectomy (db UNX +Ang-II). As with the
angiotensin-II infusion alone, db UNX +Ang-II mice de-
veloped similar level of hypertension (Figure 5A) with
low plasma renin content (Figure 5B). After 4 weeks, we
saw a modest increase in the development of mesangial
matrix expansion in db uNX +Ang-II mice compared to
the db UNX, but lower than the extent of the injury seen
in db RAS mice (Figure 5C, 5D). Similarly, we observed
an increase in interstitial fibrosis and fibronectin depos-
ition in the db UNX + Ang-II mice compared to the db
UNX (Figure 5C, 5E, 5F), but similar to those observed
in the AngII group. However, the db UNX +Ang-II mice
Figure 4 Db RAS mice developed albuminuria to a greater extent that the WT RAS mice. A. db RAS experienced persistent and progressive
albuminuria compared to the transient albuminuria experienced by WT RAS. Albuminuria was measured in spot urine sample and normalized to urine
creatinine. Data are presented as means ± SE. ** p <0.01, *** p < 0.001 vs. WT sham with the same time point. §§ p < 0.01, §§§ p < 0.001 vs. WT
RAS or db sham with the same time point. Statistical significance was determined by 2-way ANOVA followed by Tukey adjusted post-hoc
comparison. B-D. Representative electron microscope (EM) images of contralateral kidneys at 6 weeks post-surgery. db RAS mice showed significant
area of mesangial matrix expansion (yellow arrows) (B) in comparison to WT RAS or db sham, along with thickened basement membrane (red arrows)
(C) and podocyte fusion (blue arrows) (D). These changes were not observed in the WT mice (with or without RAS) or db sham mice. Images in B are
taken at 2900× magnification while C and D are taken at 9600× magnification. E. Morphometric analysis showed significant increase in basement
membrane thickness of db RAS compared to WT RAS and db sham. Data are presented as means ± SE. * p < 0.05. Statistical significance was
determined by one-way ANOVA followed by Tukey adjusted post-hoc comparison.
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to db RAS, indicating other factors that might be con-
tributing to the development of this injury. Interest-
ingly, db UNX +Ang-II mice developed a similar degree
of albuminuria as seen in the db RAS mice at 2 weeks
(Figure 5F), but returned to baseline levels at 4 weeks.
Db RAS mice developed greater renal inflammation
We and other investigators have shown that the stenotic
kidney can become a source of inflammatory cytokines
and chemokines [14,17-19] that can cause remote injur-
ies. Therefore, we sought to determine if the db RAS
mice experienced higher degree of inflammation in com-
parison to the control groups. Histological examination
showed a significantly higher infiltration of F4/80 renal
macrophages in the contralateral kidney of the db RAS
mice compared to the other models (Figure 6A, 6B). RT-
PCR of Ccl2 and Il-6 as marker of inflammation in the
contralateral or remaining kidneys of the mice showed
significantly higher elevation of both Ccl2 and Il-6
mRNA in the db RAS compared to the other models
(Figure 6C, 6D). In contrast, both db RAS and dbUNX + Ang-II showed similar elevation of serum
CCL2 and IL-6.
Reduction of blood pressure ameliorates chronic injury to
the contralateral kidney of db RAS mice
To further determine the role of angiotensin II in this
process, we sought to determine whether lowering blood
pressure by angiotensin-II receptor blocker (ARB) or by
hydralazine, which induces vasodilation without direct
effects on the renin angiotensin system, would amelior-
ate renal damage observed in the contralateral kidney
of db RAS mice. Treatment of db RAS mice with either
ARB or hydralazine was similarly effective in reducing
blood pressure to baseline levels (Figure 7A). Both ARB
and hydralazine treated mice had no significant eleva-
tion of plasma renin content at 4 weeks (Figure 7B).
ARB and hydralazine were effective in reducing but
not abolishing glomerular mesangial matrix expansion
(Figure 8A, 8B), glomerular de novo fibronectin expres-
sion, interstitial fibrosis (Figure 8C), and reduced influx of
macrophages into the contralateral kidney (Figure 8D).





































































































































































Figure 5 Angiotensin-II induced hypertension (Ang-II), unilateral nephrectomy (UNX), and combination of both angiotensin-II and
unilateral nephrectomy (UNX + Ang-II) unable to re-produce all aspects of injury seen in the contralateral kidney of db RAS mice.
A. Systolic BP were elevated to a similar extent in db RAS, db Ang-II and db UNX + Ang-II (p = ns) and not elevated in the db UNX mice. ** p < 0.01
vs. db sham. B. Plasma renin activity (PRA) was elevated only in the db RAS. PRA was assessed by angiotensin-I production. C. Representative histological
images of contralateral kidney of db RAS and db sham mice, left kidney of db Ang-II mice, and remnant kidney of db-UNX and db UNX+Ang-II mice as
stained with periodic acid schiff (PAS), fibronectin, and Masson’s Trichrome. PAS images are taken at 400× while fibronectin and trichrome images are
taken at 200×. D. Mesangial matrix expansion was seen on db RAS, and to a lesser extent on the db UNX and db UNX + Ang-II, but not on db sham or
db Ang-II. E. Interstitial fibrosis was increased to a similar extent in all models as assessed by trichrome stained section. F. Interstitial fibronectin deposition
was increased to a greater extent in db RAS mice compared to all other models. For B, D, and F, * p <0.05 vs. db sham, db Ang-II, db UNX or db UNX +
Ang-II. G. Urine albumin excretion is highest in db RAS and db UNX + Ang-II mice at 2 weeks post-surgery. * p < 0.05, ** p < 0.01 vs. db sham. § p <0.05
vs. db Ang-II. Albuminuria was measured in spot urine sample and normalized to urine creatinine. Data are presented as means ± SE. Statistical
significance was determined by one-way ANOVA followed by Tukey adjusted post-hoc comparison.





































































































Figure 6 Db RAS mice experienced higher level of inflammation compared to db mice with Angiotensin-II induced hypertension
(Ang-II), unilateral nephrectomy (UNX), or both angiotensin-II and unilateral nephrectomy (UNX + Ang-II). A. Representative
immunostaining of renal macrophages in paraffin section of contralateral or remnant kidneys. Macrophages were stained with anti F4/80
antibody. All images are taken at 200× magnification. B. Contralateral kidney of db RAS mice experienced higher increase of renal macrophage
infiltration compared to db Ang-II, db UNX, or db UNX + Ang-II. ** p < 0.01 vs. db sham or db Ang-II, § p < 0.05 vs. db UNX or db UNX + Ang-II.
Macrophages were stained with F4/80 antibody and quantified with NIS image analysis system. C-D. RT-PCR analysis of Ccl2 (C) and Il-6 (D) mRNA
as normalized to 18 s showed that contralateral kidney of db RAS mice produces more inflammatory cytokines and chemokines compared to db
Ang-II, db UNX, or db UNX + Ang-II. * p < 0.05 for db RAS vs. all other groups. E-F. Serum CCL2 (E) and IL-6 (F) concentration is elevated to a similar
extent in db RAS and db UNX + Ang-II (p = ns). * p < 0.05 vs. db sham, db UNX, or db Ang-II. Data are presented as means ± SE. Statistical significance
was determined by one-way ANOVA followed by Tukey adjusted post-hoc comparison.
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(Figure 8E).
Discussion
A role for hypertension in the development of renal le-
sions in db/db mice has not been clearly established
[20-25]. We found that db sham mice did not develop
spontaneous hypertension, while db RAS mice develop
hypertension to an extent that is similar to that observed
in WT RAS mice, yet associated with transient but more
prolonged increases in plasma renin activity and greater
renal Ren1 expression. This persistent increase in plasma
renin activity in db RAS mice may reflect interactionsbetween hemodynamic forces associated with renovascu-
lar hypertension and the diabetic mileau. Despite similar
level of systolic blood pressure, the contralateral kidney
of db RAS mice developed chronic renal injury charac-
terized by development of mesangial matrix expansion,
interstitial fibrosis, tubular atrophy, and interstitial in-
flammation, as opposed to the contralateral kidneys in a
number of other strains of non-diabetic mice subjected
to RAS [5,16,26]. Glomerular histopathologic alterations
in the contralateral kidney of db/db mice were striking,
and reminiscent of those observed in progressive human
diabetic nephropathy, with severe and diffuse mesangial





















































Figure 7 Both Angiotensin Receptor Blocker (ARB) and hydralazine lower systolic blood pressure in db RAS. A. Systolic blood pressure
measurement of db sham or db RAS mice given no treatment, angiotensin receptor blocker (ARB) or hydralazine (Hyd). B. Both ARB and
hydralazine treated mice have decreased plasma renin activity at 4 weeks post RAS as assessed by angiotensin I production. * p < 0.05, *** p < 0.001
for db RAS vs. all other groups.
Hartono et al. BMC Nephrology 2014, 15:58 Page 11 of 14
http://www.biomedcentral.com/1471-2369/15/58induction of hypertension. Mesangial matrix expansion
consistently was far more extensive than in age-matched
db sham mice, and was associated with de novo glom-
erular fibronectin expression. Older db/db mice develop
glomerular basement membrane thickening, but quanti-
tative studies in this model have not yet been reported
[27-29]. We found an increase of glomerular basement
membrane thickness in the contralateral db RAS kidney
by six weeks post-surgery, as assessed by morphometric
analysis of electron microscopic images, a well-recognized
feature of evolving diabetic nephropathy. Glomeruli in
these kidneys (but not in WT RAS) showed extensive ef-
facement of visceral epithelial cell foot processes, a mor-
phologic correlate of the progressive albuminuria observed
in these mice. At all time-points, urine albumin excretion
was significantly greater in db RAS than db sham mice.
Based on these observations, we conclude that renovascu-
lar hypertension markedly accelerates renal disease pro-
gression in db/db mice as characterized by glomerular
mesangial matrix expansion, progressive interstitial fibrosis
and inflammation, and breakdown of the filtration barrier.
This is in accordance with clinical observations indicating
that progression of diabetic nephropathy is accelerated in
patients with hypertension.
We infused db/db mice with angiotensin II for 4 weeks
to address a potential role of angiotensin II induced
hypertension on renal architecture in db/db mice. These
mice developed hypertension to levels similar to those
attained in db RAS mice, yet we observed a minimal in-
crease in mesangial matrix deposition and no evidence
of de novo glomerular fibronectin deposition. Neverthe-
less, db Ang-II developed albuminuria similar to that ob-
served in db RAS mice and to that reported following
angiotensin II infusion to non-diabetic mice [30,31].
Taken together, these observations suggest that the pro-
gressive and bilateral renal injury in db RAS mice is notmechanistically related to elevated angiotensin II levels
alone, although angiotensin II plays a major role in de-
velopment of albuminuria in this model [7,8]. This find-
ing underscores a critical role for activation of the renin-
angiotensin system in the development of albuminuria
and provides a therapeutic rationale for the widespread
use of renin-angiotensin inhibitors in treatment of
chronic kidney disease.
We then sought to determine whether hyperfiltration
associated with unilateral nephrectomy may underlie the
progressive renal damage observed in the contralateral
db RAS kidney. Unlike db RAS or db Ang-II mice, db
UNX did not develop significant hypertension. Db UNX
also did not develop increased urine albumin excretion
that was observed in the db RAS or db Ang-II. However,
as shown before, db/db mice with unilateral nephrec-
tomy did develop greater glomerular mesangial matrix
expansion than age-matched db/db mice with two kid-
neys [8,32], although its extent was less than that of db
RAS mice. Although few investigators have directly re-
ported the extent of interstitial fibrosis in this model,
db/db mice evaluated at 14 – 18 weeks post UNX exhib-
ited a modest increase in interstitial inflammation, inter-
stitial volume, and number of tubules showing dilation
or atrophy [8,32,33]. In the current study, we find that
db UNX mice, in striking contrast to db RAS mice, do
not develop significant interstitial fibrosis or tubular at-
rophy at 4 weeks post UNX. Therefore, glomerular
mesangial matrix expansion in db/db mice can be attrib-
uted at least in part to hemodynamic factors associated
with hyperfiltration, whereas elevation of blood pressure
appears to play a major role in development of albumin-
uria in db/db mice.
As Angiotensin-II induced hypertension and UNX alone
only recapitulate some features of renal injury seen in the




























































































Figure 8 Both Angiotensin Receptor Blocker (ARB) and hydralazine afford similar attenuation of injury in the contralateral kidney of
db RAS. A. Representative histological images of contralateral kidney of db/db mice undergoing RAS or sham surgery and treated with either
ARB or hydralazine (Hyd) as stained with periodic acid schiff (PAS), fibronectin (FN), Masson’s Trichrome, and anti F4/80 antibody. PAS images are
taken at 400× magnification while fibronectin, trichrome and F4/80 images are taken at 200× magnification. B. Both ARB and hydralazine
attenuated mesangial matrix expansion to a similar degree in the contralateral kidney of db mice with RAS. C. Both ARB and hydralazine
attenuated development of interstitial fibrosis to a similar degree in the contralateral kidney of db mice with RAS. D. Both ARB and hydralazine
reduced renal macrophage infiltration into the contralateral kidney of db RAS mice. E. ARB but not hydralazine attenuated albuminuria in the db
RAS mice. * p < 0.05, ** p < 0.01.
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mice developed all the features seen in the db RAS mice,
namely mesangial expansion, interstitial fibrosis, tubular
atrophy, and albuminuria, but the severity of injury ob-
served in the contralateral kidney of db RAS mice was
greater than that of db UNX+Ang-II mice.
To examine if hypertension was necessary for the de-
velopment of progressive renal fibrosis in the contralat-
eral kidneys of db/db mice, we treated them with ARB
or the vasodilator hydralazine, which lowered blood
pressure to levels similar to those observed in db sham
mice without significant changes in plasma renin activ-
ity. Reduction of blood pressure was effective in redu-
cing mesangial matrix expansion, fibronectin expression,
interstitial fibrosis, and tubular atrophy in the contralat-
eral kidney of db RAS mice. However, urine albumin
excretion was significantly reduced by ARB only. There-
fore, we conclude that hypertension plays an essential
role for the development of chronic renal lesions in the
contralateral kidney of db/db mice subjected to RAS,
while increase level of angiotensin II plays a role in the
development of albuminuria. Interestingly, while both
drug treatments attenuate the development of renal in-
jury, both do not abolish it. Given the less severe injury
observed in the db UNX+Ang-II, these results point to
some other factor independent of blood pressure elevation
and hyperfiltration process that is mediated by the sten-
otic kidney, possibly by the activated RAAS.
We and other investigators have shown that the sten-
otic kidney experienced considerable oxidative stress
[14,17] and produced substantial level of inflammatory
cytokines [18,19]. Indeed, in comparison to the other
models, contralateral kidney of db RAS exhibited signifi-
cantly higher expression of the inflammatory chemokine
CCL2 and the inflammatory cytokine IL-6, both of
which represent prognostic of development of renal in-
jury [34-36]. Nonetheless, db RAS showed similar in-
creased in serum CCL2 and IL-6 to db UNX +Ang-II.
However, although serum levels of CCL2 might be ele-
vated in diabetic patients, they are not associated to the
development of albuminuria, renal macrophage influx,
or interstitial fibrosis [37-39]. Instead, both urine CCL2
and IL-6 excretion – reflecting production of these in-
flammatory molecules within the kidney itself – have
been shown to correlate significantly with progression of
renal injury [37,38,40]. Furthermore, increased albumin-
uria may itself aggravate tubular injury and accelerate
development of renal injury by increasing tubular CCL2
and IL-6 production [41,42].
Conclusion
In summary, renovascular hypertension accelerates de-
velopment of diabetic renal injury in db/db mice that re-
capitulates many of the features of chronic renal diseasein subjects with diabetes and hypertension and markedly
accelerated the progression of chronic renal disease. As
hypertension induced by angiotensin II infusion was not
sufficient to reproduce these lesions, we believe that inter-
actions between the diabetic milieu and hemodynamic
forces associated with hyperfiltration were necessary to
produce progressive renal disease in db/db mice. Although
combination of Angiotensin-II infusion and unilateral
nephrectomy are able to replicate many features of injury
observed in the db RAS, the db RAS model is likely more
physiologically relevant to the development of diabetic ne-
phropathy in patients with both diabetes and RAS, and will
allow the development of mechanistic studies to identify
critical pathways related to inflammation, fibrosis, oxidative
stress, and cell cycle regulation that are responsible for the
development and progression of diabetic renal disease.
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